Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
601 vs Ranibizumab for Macular Edema Secondary to CRVO
NCT04667910Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 601 in macular edema secondary to central retinal vein occlusion (ME-CRVO), sponsored by 3S Guojian Pharmaceutical. Started Jan 2021; status: completed.
02
Drugs
601
03
Conditions
macular edema secondary to central retinal vein occlusion (ME-CRVO)
Beyond the preview
Go deeper on NCT04667910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667910.